FILING ANALYSIS · THURSDAY, OCTOBER 29
SUPERNUS PHARMACEUTICALS, INC. SUPN — 8-K: Results of Operations and Financial Condition
positive
Supernus reported record total revenues of $226.8 million in Q3 2026, an 18% increase year-over-year, driven by strong growth in its four key products, and announced the expected closure of its merger with Indivior Pharmaceuticals on November 2, 2026. The company's financial performance and impending merger could positively impact its stock price.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →